Evidence map›Paper›PMID 14641932›Full record

ArticleBMC cancer2003

Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data.

Marc E Lenburg, Louis S Liou, Norman P Gerry, Garrett M Frampton, Herbert T Cohen, Michael F Christman

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in BMC cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 6 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 6 syntheses or guidelines pooled it, 279 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Prognostic Significance ofBiomedicines · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.Journal of experimental & clinical cancer research : CR · 2022
    Review
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marc E LenburgDepartment of Genetics & Genomics, Boston University School of Medicine 715 Albany Street, E613 Boston, Massachusetts 02118, USA. mlenburg@bu.edu
Louis S Liou
Norman P Gerry
Garrett M Frampton
Herbert T Cohen
Michael F Christman
Boston University · US

Funding

VHL, Jade-1 and protein stability in renal cancerR01CA079830 · NCI · BOSTON MEDICAL CENTER · PI COHEN, HERBERT TOD · 1999 to 2014
$4.0M
NCI NIH HHS R01 CA079830
6 · The paper itself

Abstract

backgroundRenal cell carcinoma is a common malignancy that often presents as a metastatic-disease for which there are no effective treatments. To gain insights into the mechanism of renal cell carcinogenesis, a number of genome-wide expression profiling studies have been performed. Surprisingly, there is very poor agreement among these studies as to which genes are differentially regulated. To better understand this lack of agreement we profiled renal cell tumor gene expression using genome-wide microarrays (45,000 probe sets) and compare our analysis to previous microarray studies.

methodsWe hybridized total RNA isolated from renal cell tumors and adjacent normal tissue to Affymetrix U133A and U133B arrays. We removed samples with technical defects and removed probesets that failed to exhibit sequence-specific hybridization in any of the samples. We detected differential gene expression in the resulting dataset with parametric methods and identified keywords that are overrepresented in the differentially expressed genes with the Fisher-exact test.

resultsWe identify 1,234 genes that are more than three-fold changed in renal tumors by t-test, 800 of which have not been previously reported to be altered in renal cell tumors. Of the only 37 genes that have been identified as being differentially expressed in three or more of five previous microarray studies of renal tumor gene expression, our analysis finds 33 of these genes (89%). A key to the sensitivity and power of our analysis is filtering out defective samples and genes that are not reliably detected.

conclusionsThe widespread use of sample-wise voting schemes for detecting differential expression that do not control for false positives likely account for the poor overlap among previous studies. Among the many genes we identified using parametric methods that were not previously reported as being differentially expressed in renal cell tumors are several oncogenes and tumor suppressor genes that likely play important roles in renal cell carcinogenesis. This highlights the need for rigorous statistical approaches in microarray studies.

Indexed as

AgedCarcinoma, Renal CellFemaleGene Expression ProfilingHumansKidney NeoplasmsMaleMiddle AgedOligonucleotide Array Sequence AnalysisRNA, NeoplasmRNA, Neoplasm

Identifiers

PMID14641932
PMCPMC317310
OpenAlexW2138289111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.